Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
REATA PHARMACEUTICALS INC (RETA) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/26/2023 8-K Quarterly results
07/31/2023 8-K Quarterly results
07/28/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Biogen to Acquire Reata Pharmaceuticals"
06/07/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/10/2023 8-K Investor presentation, Quarterly results
Docs: "Three Months Ended March 31 2023 2022 Consolidated Statements of Operations Collaboration revenue License and milestone $ - $ 893 Other revenue 195 21 Total collaboration revenue 195 914 Expenses Research and development 55,477 39,804 Selling, general and administrative 54,885 24,841 Depreciation 288 308 Total expenses 110,650 64,953 Other income , net Loss from operations Benefit from taxes on income - Net loss $ $ Net loss per share—basic and diluted $ $ Weighted-average number of common shares used in net loss per share basic and diluted 36,948,063 36,412,621 As of As of Condensed Consolidated Balance Sheet Data Cash and cash equivalents and marketable debt securities $ 320,959 $ 387,514 Operating lease right-of-use assets 103,807 105,258 Working capital 277,944 338,810 Total assets...",
"1st Quarter 2023 Financial Results and Update on Operational Progress and Development Programs May 10, 2023 Exhibit 99.2"
03/01/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "THIRD AMENDED AND RESTATED BYLAWS OF REATA PHARMACEUTICALS, INC. Effective as of March 1, 2023 Preamble These bylaws are subject to, and governed by, the General Corporation Law of the State of Delaware and the certificate of incorporation of Reata Pharmaceuticals, Inc., a Delaware corporation . In the event of a direct conflict between the provisions of these bylaws and the mandatory provisions of the Delaware General Corporation Law or the provisions of the Certificate of Incorporation, such conflicting provisions of the Delaware General Corporation Law or the Certificate of Incorporation, as the case may be, will be controlling. Article I"
11/08/2022 8-K Investor presentation, Quarterly results
Docs: "Three Months Ended Nine Months Ended September 30 September 30 2022 2021 2022 2021 Consolidated Statements of Operations Collaboration revenue License and milestone $ - $ 5,529 $ 1,648 $ 7,127 Other revenue 540 1,862 568 3,430 Total collaboration revenue 540 7,391 2,216 10,557 Expenses Research and development 43,485 39,430 122,620 114,377 General and administrative 27,270 25,736 77,254 68,440 Depreciation 272 320 853 880 Total expenses 71,027 65,486 200,727 183,697 Other income , net Loss before taxes on income Benefit from taxes on income - - 669 Net loss $ $ $ $ Net loss per share—basic and diluted $ $ $ $ Weighted-average number of common shares used in net loss per share basic and diluted 36,536,919 36,387,560 36,472,903 36,297,766 As of As of Condensed Consolidated Balance Shee...",
"3rd Quarter 2022 Financial Results and Update on Development Programs November 8, 2022 Exhibit 99.2"
11/07/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "TO: ALL CURRENT STOCKHOLDERS OF REATA PHARMACEUTICALS, INC."
08/08/2022 8-K Quarterly results
07/12/2022 8-K Quarterly results
06/09/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
03/02/2022 8-K Quarterly results
02/28/2022 8-K Quarterly results
02/07/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/08/2021 8-K Investor presentation, Quarterly results
Docs: "EX-99.1_PR",
"Company slides"
10/22/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/20/2021 8-K Quarterly results
08/09/2021 8-K Investor presentation, Quarterly results
Docs: "EX-99.1_PR",
"Company slides"
06/23/2021 8-K Quarterly results
06/11/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
04/15/2021 8-K Quarterly results
03/01/2021 8-K Quarterly results
01/11/2021 8-K Quarterly results
12/03/2020 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Underwriting Agreement, by and among Reata Pharmaceuticals, Inc. and the Representatives",
"Opinion of Vinson & Elkins L.L.P"
11/09/2020 8-K Conference call transcript
Docs: "Transcript of earnings call held on November 9, 2020"
11/09/2020 8-K Quarterly results
Docs: "EX-99.1_PR",
"CARDINAL top-line data results press release",
"Company management presentation slides"
08/27/2020 8-K Quarterly results
08/10/2020 8-K Quarterly results
07/30/2020 8-K Quarterly results
07/07/2020 8-K Quarterly results
06/24/2020 8-K Quarterly results
06/11/2020 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy